SEC Form 4 · accession 0001209191-18-012262
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vaseem Mahboob
Director
Period of report
Jan 30, 2018
Accepted (ET)
Feb 22, 2018 · 2:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $9.80 | Jan 30, 2018 | A | 24,000 | A | — | Jan 29, 2021 | Common Stock | 24,000 | 24,000 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 30, 2018 | A | 6,000 | A | — | — | Common Stock | 6,000 | 6,000 | D |
Explanation of responses
- F1The option vests in 36 equal monthly installments and will be fully vested and exercisable on January 30, 2021.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3Represents shares issuable upon the vesting of restricted stock units ("RSUs") awarded to the Reporting Person on January 30, 2018. The RSUs vest on the one year anniversary of the date of grant, so long as there has been no break in the Reporting Person's continuous service through such date.